News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Immunic appoints Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer, bringing extensive experience in neurology drug development and regulatory approvals. Company transitions into a fully integrated commercial-stage entity -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic to Participate in Scientific and Medical Conferences in April
Immunic, Inc. to participate in scientific and medical conferences in April. Presentation on vidofludimus calcium for treating multiple sclerosis at the Neuroimmunology Drug Development Summit and AAN Annual Meeting